SyNoesis Therapeutics is a company developing innovative treatments for incurable diseases of the Central Nervous System and for improving cognitive function of the brain during aging.
SyNoesis was founded in 2017 in Cyprus and in 2019 in Greece by Dr. Athanasios Spathis. The company also consists of Dr Alexander Breidenbach, former Vice President of Neurosciences at Roche’s headquarters in Switzerland and Dr Peter Sennhenn, Director of Medicinal Chemistry at the company with previous experience in various pharmaceutical companies including Boehringer Ingelheim in Germany. The company collaborates with a network of experts in Europe, Switzerland and America, and maintains active partnerships with academic institutions, particularly in Crete with FORTH, where it participates in a funding program coordinated by Professor Dr. Garinis and Professor Dr. Tavernarakis.
Additionally, SyNoesis is developing small molecules with criteria to specifically activate a protein – nuclear receptor in the brain called Nurr1, which has been genetically identified in Parkinson’s disease patients and has been found to have an in-depth neuroprotective and anti-inflammatory role in the brain in vivo in a variety of neuropathological animal models.
Lastly, alongside the development of small molecules for the treatment of Parkinson’s disease, SyNoesis is focusing on studying the gut microbiome to determine its therapeutic potential for treating neurodegenerative diseases and improving cognitive function in dementia and ageing.
